Here are three things to know about the deal.
1. Cogentix manufactures various urology and endourology products. The company was formed via the merger of two devicemakers — Uroplasty and Vision-Sciences — in 2015, according to StarTribune.
2. Laborie, a urology health company, will acquire Cogentix for $3.85 per share, representing a 28 percent premium over the stock’s average closing price in the last 30 days.
3. Cogentix expects the deal to close in the second quarter of 2018.
More articles on supply chain:
Pfizer sells neurology drug to Biogen in nearly $600M deal: 4 things to know
4 latest FDA approval
FDA approves world’s smallest heart valve for newborns
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
